MANNKIND CORP

Read how MannKind Corp’s upcoming ATTD 2026 data could ignite Afrezza’s future, boost investor confidence, and reshape the inhaled insulin market.

Explore MannKind’s biotech journey—high P/E optimism, volatile stock, and conference insights on its innovative diabetes, cancer, and autoimmune therapies.

Explore MannKind’s biopharma strategy, stock performance, and innovation pipeline in diabetes, cancer, and autoimmune therapy markets.

New pediatric trial for MannKind’s inhaled insulin Afrezza targets kids with type‑1 diabetes, boosting the biopharma firm’s diabetes pipeline and market potential.

Explore MannKind’s biotech journey—insider sales, high P/E, negative book value, and a $1.6B cap—while spotlighting its diabetes therapy Afrezza and future growth potential.

Investors weigh MannKind Corp.’s CEO share sale, high P/E, and trading consolidation—what it means for biotech stock value and future prospects.

FDA approves MannKind’s FUROSCIX for children, boosting its inhaled‑therapeutic line and market outlook amid CEO share sale.

Explore MannKind Corp’s biotech stock—volatility, insider sales, high P/E and negative P/B— and what it signals for investors.

Explore MannKind Corporation’s biopharma journey—its $1.72B market cap, focus on diabetes, cancer, and autoimmune therapies, and recent stock trends.

Explore MannKind Corp’s biotech prospects, market volatility, and strategic challenges as it seeks to diversify beyond Afrezza and secure investor confidence.